Please assess the completion status of the following clinical trial:

Trial Title: A Phase 3, Vehicle-controlled Efficacy and Safety Study of IDP-123 Lotion in the Treatment of Acne Vulgaris (301)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female at least 9 years of age and older;~2. Written and verbal informed consent must be obtained. Subjects less than age of consent must sign an assent for the study and a parent or a legal guardian must sign the informed consent (if subject reaches age of consent during the study they should be re-consented at the next study visit);~3. Subject must have a score of 3 (moderate) or 4 (severe) on the Evaluator's Global Severity assessment at the baseline visit;~4. Subjects with facial acne inflammatory lesion (papules, pustules, and nodules) count no less than 20 but no more than 50;~5. Subjects with facial acne non-inflammatory lesion (open and closed comedones) count no less than 25 but no more than 100;~6. Subjects with two or fewer nodules~Exclusion Criteria:~1. Use of an investigational drug or device within 30 days of enrollment or participation in a research study concurrent with this study;~2. Any dermatological conditions on the face that could interfere with clinical evaluations such as acne conglobata, acne fulminans, secondary acne, perioral dermatitis, clinically significant rosacea, gram-negative folliculitis, dermatitis, eczema;~3. Any underlying disease(s) or some other dermatological condition of the face that requires the use of interfering topical or systemic therapy or makes evaluations and lesion count inconclusive;~4. Subjects with a facial beard or mustache that could interfere with the study assessments;~5. Subjects with more than two (2) facial nodules;~6. Evidence or history of cosmetic-related acne

- Gender: ALL
- Minimum Age: 9 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- IDP-123 Lotion (Type: EXPERIMENTAL): Tazarotene 0.045% Lotion
- IDP-123 Vehicle Lotion (Type: PLACEBO_COMPARATOR): Vehicle Lotion

Based on this trial design, predict the completion outcome and termination type (if applicable).